You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Grassroots efforts are leading the way in a number of commercial and non-commercial screening tests in development.
NEB plans to expand its product lines into new areas of research including genome editing, the companies said.
Last week's SynBioBeta conference was indicative of the high degree of interest in the synthetic bio space from omics research tool vendors.
This week's news includes Adaptive Biotechnologies, Thermo Fisher Scientific, TATAA Biocenter, and New England Biolabs.
The new partnership will support the analysis of glycans in 30,000 human samples by the end of 2021.
New England Biolabs is using Avacta's affimers with a development-stage research and diagnostic assay that could launch as early as next year.
The partnership will allow customers using NEBNext Direct target enrichment products to analyze data with the Bluebee platform.
The two companies will work to characterize new Cas nucleases, and NEB will then manufacture and commercially distribute the nucleases globally.
President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.
Wired reports that Oxitec has now developed a genetically modified fall armyworm.
A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.
In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.